BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 32593225)

  • 1. Soluble immune checkpoints CTLA-4, HLA-G, PD-1, and PD-L1 are associated with endometriosis-related infertility.
    Santoso B; Sa'adi A; Dwiningsih SR; Tunjungseto A; Widyanugraha MYA; Mufid AF; Rahmawati NY; Ahsan F
    Am J Reprod Immunol; 2020 Oct; 84(4):e13296. PubMed ID: 32593225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients.
    Omura Y; Toiyama Y; Okugawa Y; Yin C; Shigemori T; Kusunoki K; Kusunoki Y; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Ohi M; Kusunoki M
    Cancer Immunol Immunother; 2020 Dec; 69(12):2533-2546. PubMed ID: 32577816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of Soluble Forms of the Immune Checkpoint Components PD-1/PD-L1/B7-H3, CD314/ULBP1, and HLA-G in Peripheral Blood of Melanoma Patients Receiving Blockers of Programmed Cell Death Protein PD-1.
    Gershtein ES; Mochalova AS; Korotkova EA; Samoilova EV; Vashketova OI; Kuz'min YB; Sokolov NY; Kushlinskii NE
    Bull Exp Biol Med; 2023 Aug; 175(4):481-486. PubMed ID: 37773572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.
    Singh L; Singh MK; Rizvi MA; Pushker N; Bakhshi S; Sen S; Kashyap S
    Br J Ophthalmol; 2021 Jan; 105(1):48-56. PubMed ID: 32277010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
    Zhou J; Mahoney KM; Giobbie-Hurder A; Zhao F; Lee S; Liao X; Rodig S; Li J; Wu X; Butterfield LH; Piesche M; Manos MP; Eastman LM; Dranoff G; Freeman GJ; Hodi FS
    Cancer Immunol Res; 2017 Jun; 5(6):480-492. PubMed ID: 28522460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
    Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M
    Front Immunol; 2020; 11():580335. PubMed ID: 33224142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer.
    Chen QY; Chen YX; Han QY; Zhang JG; Zhou WJ; Zhang X; Ye YH; Yan WH; Lin A
    Front Immunol; 2021; 12():679090. PubMed ID: 34054869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated Soluble PD-L1 in Pregnant Women's Serum Suppresses the Immune Reaction.
    Okuyama M; Mezawa H; Kawai T; Urashima M
    Front Immunol; 2019; 10():86. PubMed ID: 30833943
    [No Abstract]   [Full Text] [Related]  

  • 9. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
    Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
    Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased serum soluble programmed cell death ligand-1 level as a potential biomarker for missed miscarriage.
    Li Q; Chen C; Wu J; Poon LC; Wang CC; Li TC; Zhang T; Guo X; Song L; Wang X; Zhang Q; Ye Z; Yang Y; Lu J; Yao J; Ye D; Wang Y
    Hum Reprod; 2023 Nov; 38(11):2128-2136. PubMed ID: 37671597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.
    Takeuchi M; Doi T; Obayashi K; Hirai A; Yoneda K; Tanaka F; Iwai Y
    Immunol Lett; 2018 Apr; 196():155-160. PubMed ID: 29366663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients.
    Pawłowska A; Kwiatkowska A; Suszczyk D; Chudzik A; Tarkowski R; Barczyński B; Kotarski J; Wertel I
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
    Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
    [No Abstract]   [Full Text] [Related]  

  • 14. Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis.
    Yan X; Gu Y; Wang C; Sun S; Wang X; Tian J; Wang M; Ji X; Duan X; Gao H; Fang Q; Dong W; Zhang X; Xue Q
    Clin Immunol; 2019 Oct; 207():68-78. PubMed ID: 31374257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CLTA-4 Expression is Associated with the Maintenance of Chronic Inflammation in Endometriosis and Infertility.
    Abramiuk M; Bębnowska D; Hrynkiewicz R; Polak PNG; Kotarski J; Roliński J; Grywalska E
    Cells; 2021 Feb; 10(3):. PubMed ID: 33668701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus].
    Luo L; Shu M; Li S; Cai Y
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms and Circulating Plasma Protein Levels of Immune Checkpoints (CTLA-4 and PD-1) Are Associated With Posner-Schlossman Syndrome in Southern Chinese.
    Huang X; Liu X; Ye Y; Zhang T; Mei S; Zhu T; Peng S; Cai J; Yan Z; Zeng K; Nie D; Sun L; Hou X; Zhao J
    Front Immunol; 2021; 12():607966. PubMed ID: 33717091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Soluble programmed death-1 and soluble programmed death ligand 1 protein expression and immune status in patients with recurrent aphthous ulcer].
    Nan J; Liang L; Li L; Xiaoqin S; Xing J; Yang C
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2017 Jun; 35(3):286-290. PubMed ID: 28675014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
    Incorvaia L; Fanale D; Badalamenti G; Porta C; Olive D; De Luca I; Brando C; Rizzo M; Messina C; Rediti M; Russo A; Bazan V; Iovanna JL
    Oncoimmunology; 2020 Oct; 9(1):1832348. PubMed ID: 33178494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Relevance of Soluble Forms of Immune Checkpoint Molecules sPD-1, sPD-L1, and sCTLA-4 in the Diagnosis and Prognosis of Ovarian Cancer.
    Świderska J; Kozłowski M; Nowak K; Rychlicka M; Branecka-Woźniak D; Kwiatkowski S; Pius-Sadowska E; Machaliński B; Cymbaluk-Płoska A
    Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.